| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.23▼ | 4.28▼ | 4.29▼ | 4.32▼ | 4.19▼ |
| MA10 | 4.26▼ | 4.28▼ | 4.33▼ | 4.25▼ | 4.71▼ |
| MA20 | 4.28▼ | 4.34▼ | 4.33▼ | 4.27▼ | 4.92▼ |
| MA50 | 4.29▼ | 4.30▼ | 4.27▼ | 4.88▼ | 4.70▼ |
| MA100 | 4.35▼ | 4.25▼ | 4.21▼ | 4.90▼ | 3.93▲ |
| MA200 | 4.32▼ | 4.23▼ | 4.53▼ | 4.95▼ | 3.76▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.010▼ | -0.014▼ | -0.018▼ | 0.043▲ | -0.150▼ |
| RSI | 28.877▼ | 36.590▼ | 40.098▼ | 41.410▼ | 41.226▼ |
| STOCH | 11.268▼ | 44.907 | 27.176 | 63.130 | 12.513▼ |
| WILL %R | -86.667▼ | -93.548▼ | -93.548▼ | -54.386 | -86.802▼ |
| CCI | -173.399▼ | -130.967▼ | -147.076▼ | 30.422 | -96.638 |
|
Monday, November 09, 2026 04:00 PM
Atea Pharmaceuticals (NASDAQ:AVIR) is targeting a mid-2027 U.S. application for its hepatitis C treatment, pending results from a second late-stage trial, and has secured a credit facility of up to ...
|
|
Monday, November 09, 2026 07:00 AM
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection Phase 3 C-FORWARD Trial for H ...
|
|
Sunday, November 08, 2026 11:00 PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/11/26 | 4.36 | 4.44 | 4.16 | 4.19 | 235,929 |
| 09/11/26 | 4.35 | 4.48 | 4.315 | 4.41 | 244,167 |
| 06/11/26 | 4.21 | 4.35 | 4.12 | 4.31 | 199,472 |
| 05/11/26 | 4.48 | 4.49 | 4.19 | 4.22 | 297,825 |
| 04/11/26 | 4.29 | 4.495 | 4.2401 | 4.46 | 268,893 |
| 03/11/26 | 4.14 | 4.33 | 4.105 | 4.17 | 391,257 |
| 02/11/26 | 4.15 | 4.29 | 3.945 | 4.10 | 330,293 |
| 30/10/26 | 4.30 | 4.32 | 4.07 | 4.11 | 349,862 |
| 29/10/26 | 4.30 | 4.50 | 4.26 | 4.31 | 280,875 |
| 28/10/26 | 4.15 | 4.27 | 4.14 | 4.27 | 326,645 |
|
|
||||
|
|
||||
|
|